Objective: In this study, we provide long-term outcome data of patients with primary central nervous system lymphoma Methods: The long-term outcomes of PCNSL patients diagnosed between 1982 and 2006 were reviewed. Neurological late neurotoxicity symptoms, neuroradiological brain atrophy and leukoencephalopathy were evaluated. Surviving patients completed the Quality of Life Questionnaire-30 and Brain Cancer Module-20. The differences in overall survival were assessed using the KaplanMeier method and log-rank test. The differences between groups in terms of each investigated parameter were analyzed using the Wilcoxon signed-rank test Results: Among 112 PCNSL patients, there were 33 (29.4%) long-term (> 5 years) survivors. The median survival of all long-term survivors was 105.7 months; of these, 8 (7.1%) were alive at the latest follow-up, with a mean survival time of 170.2 months (range, 121.8-286.4). Clinical assessment revealed severe neurotoxicity in 14 patients (42.4%), moderate neurotoxicity in 5 (15.1%), and normal status in 14 (42.4%). Correlations were seen between the neuroradiological imaging score changes and neurocognitive condition (P=0.0001), neurocognitive condition and the whole brain irradiation dose (P=0.0004), and atrophy and the whole brain irradiation dose (P=0.0035). Conclusions: A more severe clinical condition was found to be associated with increasing age and whole brain irradiation dose in long-term survivors with PCNSL.
Introduction
Primary central nervous system lymphoma (PCNSL) is a rare extranodal form of non-Hodgkin lymphoma (NHL) arising in the brain, spinal cord, leptomeninges or eyes, accounting for~3% of all primary brain tumors. Most PCNSLs are B-cell-type NHL with high-grade malignancy (1, 2) . The incidence of PCNSL is increasing in immunocompetent individuals between 50 and 80 years of age. The median overall survival (OS) of PCNSL patients treated with high-dose methotrexate (HD-MTX) chemotherapy, with or without irradiation, has improved in recent decades (3) (4) (5) . However, the relationship between whole-brain irradiation (WBIR) and neurotoxicity requires further investigation. Long-term follow-up data on PCNSL patients are limited as almost all published reports have a short-term observation period of <5 years (6) (7) (8) . For these reasons, it is necessary to accumulate long-term neurocognitive function and quality of life (QOL) data for patients with PCNSL. We have previously reported the short-term outcomes in a large cohort of PCNSL patients (9) . In the present study, we update our previous results and provide long-term survivorship data, including QOL, of long-term PCNSL survivors.
Patients and methods
The long-term outcomes of 112 PCNSL patients diagnosed between 1982 and 2006 were reviewed (9) . In brief, all patients were human immunodeficiency virus infection negative and did not present with any other immunosuppressive condition. Computed tomography (CT) or magnetic resonance imaging (MRI) scans of the craniospinal axis, thorax, abdomen and pelvis were performed for all patients with contrast enhancement. An eye examination was performed in patients with ocular symptoms. A bone marrow biopsy was not performed in all patients. Patients with systemic lymphoma were excluded from this study. The treatment regimens included WBIR, methotrexate (50 mg/ m ), pirarubicin, procarbazine, prednisone]. Salvage treatment was performed on an individual basis at the discretion of the physician. Late neurotoxicity was evaluated as previously described (9) . Patients were assessed for brain atrophy and leukoencephalopathy by repeated CT or MRI scans. Late neurotoxicity symptoms were defined as those that were diagnosed after long-term follow-up and could not be explained by any other reason. A diagnosis of severe neurotoxicity was made for patients whose lifestyles were disturbed due to progressive cognitive disorders. Moderate neurotoxicity was defined as a condition in which the patient's symptoms did not interfere with basic daily activities or in which the patient could return to work with reduced responsibilities. Patients who were able to return to work with full responsibilities were defined as normal. A grading system (0, normal; 1, minor; 2, mild; 3, moderate; 4, severe) was used in an attempt to evaluate the changes seen in: (i) ventricular size, (ii) cortical atrophy, (iii) leukoencephalopathy (diffuse white matter disease) and (iv) periventricular changes (T2-weighted high intensity of the periventricular areas) on either CT in the axial plane or T2-weighted MRI. The mean neuroradiological imaging score obtained from the scan taken at the end of radiotherapy was used as the baseline score and was compared with that of follow-up scans taken at least once a year to determine whether there had been a change in the grade.
Surviving patients completed the European Organization for Research and Treatment of Cancer QOL Questionnaire-30 (QLQ C-30) and Brain Cancer Module-20 (BN-20) (10) . Questionnaires were scored and analyzed according to the scoring manual (11) . The endpoint measurements included the proportion of surviving patients showing complete remission and the OS and event-free survival rates, as previously described by International Primary CNS lymphoma Collaborative Group (IPCG) criteria (12) . A logistic regression model was used to determine the odds ratios and 95% confidence intervals (CIs) with respect to the major clinical factors. These factors were assessed by both univariate and multivariate analyses with stepwise variable selection. The differences in OS were assessed using the Kaplan-Meier analysis and log-rank test. The differences between groups in terms of each investigated parameter were analyzed using the Wilcoxon signed-rank test. All probability values were two sided, with the cutoff for significance set at P < 0.05.
Results

Long-term survivors
The survival outcomes and characteristics of the total 112 patients are shown in Figs 1 and 2. There were 33 (29.4%) long-term survivors who have survived >5 years. The median OS and event-free survival of the long-term survivors were 105.7 (95% CI, 77-146.3) and 77 months (95% CI, 60-101), respectively. At the most recent follow-up, 8 (7.1%) of the 112 patients were alive, and the mean survival period of these survivors was 170.2 months (range, 121.8-286.4). The median age of all 33 long-term survivors was 59.0 years, the median Karnofsky performance scale (KPS) score was 69.7 and median Memorial SloanKettering Cancer Center (MSKCC) score was 2.1. Eleven (33.3%) long-term survivors died of lymphoma, eight (24.2%) died of other diseases and six (18.1%) died of unknown causes. Nineteen (57.5%) long-term survivors received the proMACE-MOPP treatment protocol, three (9.0%) R-MTX combined modality therapy, five (15.1%) MVP, four (12.1%) WBIR and two (6.0%) others, respectively.
Prognostic factors
The patient outcomes were analyzed according to several potential diagnostic and prognostic factors. Univariate analysis demonstrated that the patient age, KPS score and MSKCC score were significantly associated with OS. These variables were subsequently included in the multivariate analysis; however, the MSKCC score was the only significant variable retained in the model (P = 0.032; Table 1 ).
Neurotoxicity
Leukoencephalopathy and atrophy were detected via neuroimaging in 17 (51.5%) and 24 (75%) patients, respectively. Clinical assessment revealed severe neurotoxicity in 14 patients (42.4%), moderate neurotoxicity in 5 patients (15.1%) and normal status in 14 patients (42.4%). There was a strong correlation between the neuroradiological imaging score changes and neurocognitive condition (normal, 1.69 ± 1.65; moderate, 4.40 ± 1.81; severe, 6.92 ± 3.12; normal vs. severe, P = 0.0001). There were also strong correlations between the neurocognitive condition and WBIR dose (normal vs. severe, P = 0.0004), leukoencephalopathy and WBIR dose (P = 0.0035), and atrophy and WBIR dose (P = 0.0035) ( Table 2) .
Nineteen patients received <20 Gy WBIR; of these, 12 patients were aged ≥60 years, with normal, moderate and severe neurocognitive conditions in 7, 3 and 2 patients, respectively; and 7 patients were aged <60 years, with normal neurocognitive conditions in 6 patients and severe neurocognitive condition in 1 patient.
Fourteen patients received 30-40 Gy WBIR; of these, seven patients were aged ≥60 years, all of whom had severe neurocognitive conditions, and seven patients were aged <60 years, with normal, moderate and severe neurocognitive conditions in two, one and four patients, respectively. Thus, a more severe neurocognitive condition was associated with increasing age and higher WBIR dose.
QLQ C-30 and BN-20 scores
The QLQ C-30 and BN-20 scores of six long-term survivors are presented in Table 3 . Two survivors aged <60 years had returned to work and four survivors aged ≥60 years had retired. Five long-term survivors who had received no or 20-30 Gy of WBIR remained in reasonable health. One patient (Case 8), who had received 30 Gy WBIR at the age of 40 years, had survived for >20 years, and his neuroradiological imaging score had progressed by only 1 point. Despite this, however, the patient had a moderate QOL status.
Discussion
This study provides long-term follow-up data of patients with PCNSL who had received treatment according to our previously published protocols (9) . The median OS was 25 months, and the 5-and 10-year survival rates were 29.5% and 12%, respectively, which are comparable to those described in previous clinical studies (3) (4) (5) (6) (7) (8) . In this study, the updated results indicated the disappearance of the survival plateau we originally reported, as 14.9% of patients experienced a late relapse after 5 years of achieving complete remission (13) . Among the present survivors, two patients who did not receive WBIR had a normal neurocognitive status. Of the four patients who received low-dose WBIR at 20 or 30 Gy, two had normal and two had moderate neurocognitive conditions. However, it is difficult to determine to what extent these complications might be PCNSL related, as the impaired neurocognitive performance in longterm survivors might be affected by the normal aging process.
Late neurotoxicity is a serious problem that affects cognitive function and QOL. The incidence of late neurotoxicity in PCNSL varies from 5% to 47% and is common in patients older than 60 years (14-16). However, there are limited available long-term follow-up data for neurotoxicity, and the incidence of late neurotoxicity tends to be underestimated, since formal and systemic cognitive evaluations in PCNSL patients are not routinely performed. With extended follow-up, 40.7% of long-term survivors experienced severe neurotoxicity in our study. The majority of patients who received no or low-dose WBIR at 20 Gy had a normal neurocognitive condition, although neurotoxicity was a serious complication in a large proportion of patients older than 60 years. The risk of late neurotoxicity increases when HD-MTX and WBIR therapy are combined (17) . The synergistic adverse effects have been hypothesized to involve microvascular injury, demyelination and neurogenesis (18) .
Patients with neurotoxicity usually demonstrate abnormalities on imaging that correlate with cognitive dysfunction. Treatment-related neurotoxicity has been reported to be less frequent in long-term survivors who received chemotherapy alone (19, 20) ; however, even HD-MTX without radiation therapy is potentially neurotoxic, as 19% of survivors showed cognitive impairment after complete disease remission in one previous study (16) . Moreover, white matter abnormalities and atrophy have been documented in >50% of patients treated with HD-MTX alone (20) . Similarly, chemotherapyinduced cognitive impairment and white matter integrity changes have also been reported in breast cancer patients (21) . Chemotherapy-induced neurotoxicity is the result of a combination of decreased proliferation of neural progenitor cells, impaired hippocampal neurogenesis and damage to the white matter tracts (22) . It should be noted that the MTX and WBIR doses in our regimens were lower compared with those typically used in most protocols for PCNSL treatment. As a result, the OS was 67.8 months and the severe neurotoxicity rate of long-term survivors was 26.3% on the ProMACE-MOPP regimen. Thus, reduced doses of MTX and WBIR with polychemotherapeutic agents appeared to represent a feasible treatment approach. However, the use of dose-reduced whole-brain radiotherapy (WBRT) remains controversial; there is only one previous study in which dose-reduced WBRT (23.4 Gy) was not associated with neurotoxicity or compromised disease control (5). One report described compromised disease control with dose-reduced WBRT (30.6 Gy) (23), while chemotherapy followed by dosereduced WBRT (23.4 Gy) was not associated with cognitive decline for up to 2 years in one study (24) . MTX-based polychemotherapeutic regimens without WBRT to avoid the risk of delayed neurotoxicity have been used to increase OS, although post-treatment logterm neurocognitive testing has not been reported (4, 25, 26) . Although QOL, participation in daily activities and resuming work are not ideal measurements of neurocognition, they do provide an indirect representation of the patient's neurocognitive status. Nevertheless, large-scale prospective clinical studies assessing QOL and cognitive function as the endpoints for long-term survivors of PCNSL are warranted in the future to confirm our findings.
There were a number of limitations of this retrospective study arising from the small number of long-term survivors who received different treatment regimens in a single institution and its affiliated hospitals. However, we had more than a 10-year interval for QOL assessment; to our knowledge, this study is one of the longest follow-up QOL reports in PCNSL patients to date. As reported, even PCNSL patients treated by HD-MTX alone experience neurocognitive impairments. Although the use of dose-reduced WBIR and 
